Member Info for crumbs

Yeah Sally talked about it at AGM seemed it was not priority number one but was something they were 'working on'... I think it is important to have a modern website that is a place where potential investors can easily access info and have it presented in a way that they can 'get' scancell and what its pipeline is all about.... anyways I'm erring on the wrong plug pulled lol

Is that a code lol

Could also be the first sign of the lights going out :)

We be in for a shiny new more up to date and easier to navigate scancell website? Only seems the current one is inaccessible which I've not experienced before

Not sure he has clout there... but certainly all the clinics he will and I'm sure once the green light is flashed by the FDA the trial in US will be soon all systems go... not far for Ichor devices to travel etc...

Not to be sniffed at either:

The expertise of Poulam M. Patel ranks in the
Top 0.7%
... of 108,282 published authors worldwide on Melanoma
... from 2008 through 2019
... based on contributions to 17 articles on the topic.

Worth noting Flaherty came to scancell not the other way round... it was one of those 'lucky' moments a chance meeting leading to an agreement...Shame on the FDA holding up what could be a really transformational trial for scancell and Ichor!... if you get the top melanoma expert in the world endorsing your product via clinical success the journey to commercial product becomes so so much easier... come on FDA!

Nice I also liked the article/interview with Melief of ISA ...scancell keep very esteemed company

An obvious way would be please whoever did the 200 trade come on here and claim it... it's defo not mine though in my size area :)))..... I'm not a code believer myself but all good fun n games

Podcast from our friends at Genentech interesting and educational for anyone wanting a better understanding of what is cancer and how a better understanding of it is leading to better treatments for it..

Cancer: When Cells Go Rogue

https://www.gene.com/stories/two-scientists-walk-into-a-bar

This week is only just waking up :) ... let us hope the positive newsflow continues it is not like there are no more potential positive RNS's on the way considering the amount of work going on and the breadth of the pipeline...

One baby bio I would not want to be in today... sorry for those pi

Must be suffering the post bank holiday weekend hangover.....

This is the article:
Scancell utilises nanotechnology to amp up solid tumour vaccine
23-May-2019 By Ben Hargreaves

Scancell and Cancer Research UK use nanodelivery technology to activate the body’s immune system, boosting its ability to target and destroy cancer cells.
https://www.in-pharmatechnologist.com/Article/2019/05/23/Scancell-utilises-nanotechnology-for-cancer-vaccine

Looks like team doom have arrived to claim their 'ball'

I always got myself into the best positions.... just no one ever passed me the ball :)

All being well you won't have to wait as long as so many others of us have :))) but being an eternal being it should not matter either way.... BioNtech collaboration is due to come to an end in June, so in theory, we could get deal action there anytime after that concludes dependent on those results and modi1 has been in multiple partnership talks for a long time now and with it being so close to the clinic with all the niggles ironed out I would not be surprised to see action there anytime now too... I'm certain that trial will happen one way or another as I would bet on CRUK wanting to run it if scancell struggle to find the funds or no one else steps in... but I think they will :)

Chester scancell have talked about this....they have been critical of pharma in the past and quite rightly pharma will pay and pay big for products but they almost need to be told what to buy by others... the story of Keytruda says so so much its a really interesting story of how it is now Mercks biggest product almost to the point of them scarily being dependent on it! Checkpoint inhibitors such as Keytruda did not just appear and get snapped up by big pharmas... they began in very small cohort trials... smaller than SCIB1 trial I think for first Yerovoy trial.....It took a while for pharma to 'get it' but they do now!..... No scancell have told us the companies most interested in scancell are your other biotechs... your BioNtechs and indeed Genentech whom really as part of Roche can be considered massive... they are scientific led companies that have similar roots to scancell... Sahin of BioNtech still part of Mainz Uni... just like Lindy and Notts...they get scancell as they get the science.... things move very very slowly here but once certain stepping stones and jumped over they could move extremely fast...Hopefully, a BioNtech deal or another will be the stepping stone to take us all to the next stage and onwards to a very exciting future... but no guarantees in this game! Which is why I'm happy with such a broad pipeline and no hanging onto one result in one product.

On the fashion stakes... this is why the US arm of SCIB1 trial is invaluable to scancell and FDA hold up tragic... Keith Flaherty and his peers who want to run the SCIB1 trial in the top US clinics have real weight when it comes to treatment regimes so to get SCIB1 in those hands gives it a far better chance on clinical success of getting deal/s and going commercial than say if it were being run in some former Soviet bloc clinic ...same with modi1 and that CAB around it... those guys have clout! NHS,NICE and CRUK a proving itself modi1 would soon be in many more than 3 targets (possibly 18) and far far more terminal patients..... whom if modi1 does as it could would be seeing solid tumours melt away 3 days after a therapeutic dosage... there is no comparable treatment out there... CAR T has shown similarly in blood cancers at a huge cost and with some patients dying of the treatment.... however kite and juno sold for 11 and 9 billion with no certainty that they can ever get comparable results in solid tumours.... moditope seemingly being able to target all solid tumour cancers... without toxicity and using a peptide vaccination administered by simple injection.... potential game changer...you can imagine the headlines but unlike others the backing story would include really respected clinicians names...priceless

Well you know I have nothing against your valuations they are far better than current sp! :) just we differ on potential as mine is kite and juno and on small cohort trial data... you seem to think that is not possible... kite and juno say it is possible... same as BioNtech being worth a potential $4 billion mcap on NASDAQ... so far small cohort trial data on theirs and Genentech shared mRNA platform... how valuations are being done in this emerging market is not an exact science! Does seem to me though that a combination of validating data i.e being able to successfully treat a significant amount of patients whom there are no treatments for and an element of 'fashion' ... i.e for Kite and Juno... pharma rush to get in on CAR T... which in itself causes more interest and higher valuations around those 'fashionable' sciences .... but fundamentally we agree it will all come down to does it work... the getting it to the stage of proof is where we are at now and that we also agree on that is going to need more funds,scancell are not shy in saying so either :)

At least now we are heading into the clinic! And it does really really look like on 3 products in at least 5 targets... risk/reward